3-(4-oxo-7-pyrrol-1-yl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)-thiobenzamide | 473539-12-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-(4-oxo-7-pyrrol-1-yl-4,5-dihydro-3H-benzo[b][1,4]diazepin-2-yl)-thiobenzamide
• 英文别名: 3-(2-Oxo-8-pyrrol-1-yl-1,3-dihydro-1,5-benzodiazepin-4-yl)benzenecarbothioamide
• CAS: 473539-12-7
• 化学式: C₂₀H₁₆N₄OS
• 分子量: 360.439
• InChiKey: XWWYILJMLBSTMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
  申请人：——

  公开号：US20020198197A1

  公开（公告）日：2002-12-26

  This invention is a dihydro-benzo [b] [1,4] diazepin-2-one derivative of the formula 1 wherein R 1 , R 2 , R 3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.

  这项发明是一种二氢苯并[1,4]二氮杂环己-2-酮衍生物，其化学式如下所示：其中R1、R2、R3和Y的定义如规范中所述。该发明包括含有这些化合物的药物组合物，其制备方法以及通过给予化合物I或其药用可接受盐的有效剂量来治疗或预防急性和/或慢性神经系统疾病的方法。
• DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1379522A1

  公开（公告）日：2004-01-14
• US6548495B2
  申请人：——

  公开号：US6548495B2

  公开（公告）日：2003-04-15
• [EN] DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I<br/>[FR] DERIVES DE DIHYDRO-BENZO[B][1,4]DIAZEPINE-2-ONE UTILISES COMME ANTAGONISTES I DE MGLUR2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002083665A1

  公开（公告）日：2002-10-24

  This invention is concerned with dihydro-benzo[b][1,4]diazepin-2-one derivatives of general formula (I) wherein R?1, R2, R3¿ and Y are as defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.